Novocure stock price rises on positive pancreatic cancer trial data

LootboxPhobia · 2026-03-26T18:52:54+00:00

Novocure announced the results of its Phase 2 PANOVA-4 clinical trial, with the stock price rising by 5%. The trial showed that tumor treating fields combined with other drugs significantly improved the disease control rate in metastatic pancreatic cancer patients, reaching 74.4%. At the same time, its objective response rate was 34.6%, with a median survival of 9.7 months and good tolerability.

LootboxPhobia

2026-03-26 18:52:54

Abstract generation in progress

Investing.com – Novocure (NASDAQ: NVCR) stock rose 5% on Thursday after the company announced positive topline results from its Phase 2 PANOVA-4 clinical trial evaluating tumor treating fields for metastatic pancreatic ductal adenocarcinoma.

The trial met its primary endpoint, showing a statistically significant improvement in disease control rate compared to historical controls. Patients receiving tumor treating fields combined with atezolizumab and gemcitabine/nab-paclitaxel had a disease control rate of 74.4%, compared to 48% in the Phase 3 MPACT study, which used gemcitabine/nab-paclitaxel alone.

The study enrolled 78 patients who received the combination therapy as first-line treatment for metastatic pancreatic ductal adenocarcinoma. Disease control rate was defined as the proportion of patients with stable disease for at least 16 weeks or confirmed partial or complete response according to RECIST v1.1.

Secondary endpoints showed an objective response rate of 34.6%, with a median overall survival of 9.7 months. The median duration of tumor treating fields was 25.6 weeks, while the median systemic treatment cycle for atezolizumab and gemcitabine/nab-paclitaxel was six cycles.

The company reported that tumor treating fields were well tolerated, with device-related safety consistent with previous clinical studies. Novocure plans to present more results from PANOVA-4 at upcoming scientific forums.

This article was translated with the assistance of artificial intelligence. For more information, please see our Terms of Use.

View Original

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.

2 Likes